Cancers & treatments·Regimen libraryFirst line

Atezolizumab + bevacizumab

Checked 2026-09-09

Unresectable hepatocellular carcinoma, Child-Pugh A, varices treated

One cycle

every 21 days

21-day cycle, until progressionIntravenous

Components

Drug	Dose	Route	Days	Note
Atezolizumab Monoclonal antibody (anti-PD-L1)	1,200 mg	IV	D1
Bevacizumab Monoclonal antibody (anti-VEGF)	15 mg/kg	IV	D1

Cycles

until progression

21-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Endoscopy for varices within 6 months before starting; bleeding risk with bevacizumab.

Used in

Hepatocellular carcinoma

Trials

IMbrave150

Products

AtezolizumabBevacizumab

Source

IMbrave150, NEJM 2020

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

STRIDE (tremelimumab + durvalumab)

Unresectable hepatocellular carcinoma, first line

every 28 days

All regimens STRIDE (tremelimumab + durvalumab) →